Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Targeted Cancer Therapies

Targeted Cancer Therapies

Imaging Studies II: Positron Emission Tomography and Scintigraphy

Imaging Studies II: Positron Emission Tomography and Scintigraphy

Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same authorSame journal

Building Sustainable Theranostics Programs: Operational Models, Access, and Equity.

PET clinics·2026

Same author

From Feasibility to Durability: The Next Phase of Theranostics.

PET clinics·2026

Same author

Prostate-Specific Membrane Antigen Positron Emission Tomography-Detected Intrahepatic Cholangiocarcinoma in a Patient With Metastatic Castration-Resistant Prostate Cancer: Dual Cancer Management With Pluvicto and Intensity-Modulated Radiation Therapy.

Cureus·2025

Same author

The PANEN nomogram: clinical decision support for patients with metastatic pancreatic neuroendocrine neoplasm referred for peptide receptor radionuclide therapy.

Frontiers in endocrinology·2025

Same author

Long-term Efficacy, Survival, and Toxicity of Peptide Receptor Radionuclide Therapy in Patients With Refractory Meningioma.

Clinical nuclear medicine·2025

Same author

Dosimetry of [<sup>177</sup>Lu]Lu-DOTATATE in Patients with Advanced Midgut Neuroendocrine Tumors: Results from a Substudy of the Phase III NETTER-1 Trial.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2025

Same journal

Five Decades of [18F]Fluorodeoxyglucose-PET in Neuropsychiatric Disorders: From Brain Metabolism to Precision Functional Imaging.

PET clinics·2026

Same journal

Brain [18F]FDG PET in Subjective Cognitive Complaints: From Diagnostic Gap to Neurobiological Insight.

PET clinics·2026

Same journal

FDG PET in Movement Disorders and Parkinsonian Syndromes.

PET clinics·2026

Same journal

Brain [18F]FDG PET in Encephalitis and Postinfectious Neurocognitive Syndromes.

PET clinics·2026

Same journal

Theranostics in Nuclear Medicine: Historical, Regulatory, and Evidence Context for the Practicing Nuclear Medicine Physician.

PET clinics·2026

See all related articles

Search research articles

Related Experiment Video

Updated: May 3, 2026

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

Theranostics: When Targeted Imaging Guides Targeted Therapy.

Harshad R Kulkarni¹

¹BAMF Health, 109 Michigan Street NW, Suite 700, Grand Rapids, MI 49503, USA.

|May 1, 2026

Summary

This summary is machine-generated.

Nuclear medicine theranostics is evolving beyond matched radiopharmaceuticals. A target-centric approach uses molecular imaging as a companion diagnostic to guide various targeted therapies, enhancing precision medicine.

Keywords:

Companion diagnostics Molecular imaging Personalized medicine Radiopharmaceuticaltherapy Target verification Theranostics

More Related Videos

Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging

Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging

Published on: February 3, 2015

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

Related Experiment Videos

Last Updated: May 3, 2026

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging

Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging

Published on: February 3, 2015

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

Area of Science:

Nuclear Medicine
Molecular Imaging
Precision Medicine

Background:

Traditional theranostics pairs diagnostic scans with matched radiopharmaceutical therapy.
A broader, target-centric framework is proposed for theranostics.
Molecular imaging can serve as an in vivo companion diagnostic.

Purpose of the Study:

To advocate for a target-centric framework for theranostics.
To redefine theranostics beyond radiopharmaceuticals.
To highlight the role of molecular imaging in guiding targeted therapies.

Main Methods:

Review of current theranostic practices.
Conceptual framework development for target-centric theranostics.
Integration of molecular imaging principles with therapeutic strategies.

Main Results:

Molecular imaging verifies target expression and guides therapy selection, initiation, and monitoring.
The proposed framework encompasses antibody-drug conjugates, immunotherapy, and endocrine therapy.
Theranostics is redefined as a clinical pathway linking target biology to treatment decisions via imaging.

Conclusions:

A target-centric model enhances the application of theranostics.
Molecular imaging is crucial for personalized treatment selection and monitoring.
This expanded view of theranostics supports the evolution of precision medicine.